| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on October 8, 2003
From the Department of Medicine, University of Melbourne (K.S., M.C., G.T.L., N.J.S., G.A.D., D.W.H.), National Stroke Research Institute (N.J.S., G.A.D., D.W.H.), and Centre for Positron Emission Tomography (U.A., H.J.T.-D., J.I.S.), Austin Health, Melbourne, Victoria, Australia; Department of Neurology, John Hunter Hospital (C.R.L.) Newcastle, New South Wales, Australia; Stroke Unit, Royal Brisbane Hospital (S.J.R.), Queensland, Australia. * To whom correspondence should be addressed. E-mail: david.howells{at}unimelb.edu.au.
Background and Purpose--The ischemic penumbra is a major focus of stroke research. 18F-fluoromisonidazole (18F-FMISO), a positron emission tomography (PET) marker of hypoxic cells, has shown promise as a technique to image the penumbra in humans. Our aim was to delineate the pattern of 18F-FMISO binding in a rat middle cerebral artery transient thread-occlusion model, and correlate this with tissue outcome at 24 hours. We hypothesized that the pattern of 18F-FMISO binding would mimic that seen in humans. Methods--Thirty-eight rats underwent 2 hours transient middle cerebral artery (MCA) occlusion, and then received 18F-FMISO at time points from 0.5 to 22 hours post-MCA occlusion and were killed 2 hours later. Autoradiographic assessment of 18F-FMISO binding and assessment (triphenyltetrazolium chloride) of the area of infarction were performed on tissue slices. Results--Until 1 hour after MCA occlusion, 18F-FMISO binding was increased in the entire MCA territory, with little or no infarction visible. Over the next 5 hours, the pattern of binding evolved to a small rim of intensely binding tissue surrounding the infarct core, which itself showed reduced binding compared with the contralateral hemisphere. By 24 hours, there was minimal accumulation of 18F-FMISO binding and a large area of infarction. Conclusions--The pattern of 18F-FMISO binding rats reproduced the pattern seen in humans, consistent with this tracer being a marker of the ischemic penumbra in both species. This technique may have application in studying the ischemic penumbra in animal models, and correlating this with similar studies in humans.
Revised on December 10, 2003
Accepted on January 8, 2004
Imaging the Ischemic Penumbra with 18F-Fluoromisonidazole in a Rat Model of Ischemic Stroke
Kazuko Saita MD, PhD;
This article has been cited by other articles:
![]() |
W. Cai, R. Guzman, A. R. Hsu, H. Wang, K. Chen, G. Sun, A. Gera, R. Choi, T. Bliss, L. He, et al. Positron Emission Tomography Imaging of Poststroke Angiogenesis Stroke, January 1, 2009; 40(1): 270 - 277. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Takasawa, R. R. Moustafa, and J.-C. Baron Applications of Nitroimidazole In Vivo Hypoxia Imaging in Ischemic Stroke Stroke, May 1, 2008; 39(5): 1629 - 1637. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. J. Spratt, U. Ackerman, H. J. Tochon-Danguy, G. A. Donnan, and D. W. Howells Characterization of Fluoromisonidazole Binding in Stroke Stroke, July 1, 2006; 37(7): 1862 - 1867. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Saver Time Is Brain--Quantified Stroke, January 1, 2006; 37(1): 263 - 266. [Abstract] [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |